SuperworthUsana Health Sciences USNA
- Market cap
- $257.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- 2.2×
- Revenue, 12 months
- $913.4M
- +2% on a year ago
- Net margin
- −2.4%
- Free cash flow yield
- 6.2%
Usana Health Sciences trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $913.4M over the last twelve months, up 2% on a year earlier with a −2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $213.4M−9% | $221.1M−3% | $227.8M−8% | $212.9M−11% | $200.2M−6% | $213.6M−3% | $249.5M+10% | $235.8M+11% | $213.7M+7% | $226.2M+6% | $250.2M+0% | $223.3M−5% | |
| Cost of revenue | $42.5M−9% | $42.3M−9% | $43.1M−11% | $40.3M−7% | $39.3M−8% | $38.6M−9% | $52.4M+22% | $50.2M+24% | $48.8M+24% | $49.4M+28% | $59.4M+13% | $48.3M−4% |
| Gross profit | $170.8M−9% | $178.8M−2% | $184.7M−8% | $172.5M−12% | $161M−6% | $175.1M−2% | $197.1M+7% | $185.7M+8% | $164.9M+2% | $176.8M+1% | $190.8M−3% | $174.9M−6% |
| SG&A | $63.3M−4% | $58.7M−4% | $64.3M−4% | $64.3M−6% | $61.3M−3% | $73.3M+25% | $91.4M+42% | $81.9M+27% | $85.9M+40% | $78.1M+7% | $88.3M−4% | $82.3M+1% |
| $17.6M−22% | $24.2M+7% | $24.7M−8% | $17.8M−27% | $15.6M−11% | $8.2M−66% | $15.7M−37% | $16.7M−6% | $1.2M−92% | $3.8M−54% | $13.9M−12% | −$20M | |
| Interest expense | $43K+34% | $145K+353% | $52K+68% | $51K+19% | $49K+14% | $129K−11% | $411K+690% | $259K+408% | $49K+0% | $123K−5% | $240K−42% | $0 |
| Pre-tax income | $20.5M−12% | $26.6M+17% | $27.1M−5% | $20.2M−25% | $18.6M−9% | $10.4M−61% | $16.7M−38% | $18.8M−7% | $1.8M−90% | $4.2M−60% | $15.5M−8% | −$18.9M |
| $9.2M+11% | $9.8M−2% | $10.6M+5% | $9.8M+3% | $8M−13% | $5.9M−40% | $7.4M−30% | $8.4M−14% | $8.5M+6% | $5.8M−3% | $8.5M+14% | $9.1M+8% | |
| Net income | $11.3M−24% | $16.8M+31% | $16.5M−10% | $10.4M−40% | $10.6M−7% | $4.5M−73% | $9.4M−43% | $9.7M−7% | −$6.5M | −$1.8M | $7.5M−20% | −$21.4M |
| $0.59−24% | $0.87+32% | $0.86−10% | $0.54−39% | $0.56−5% | $0.23−74% | $0.49−43% | $0.52−4% | −$0.36 | −$0.10 | $0.41−16% | −$1.16 | |
| 19.4M+1% | 19.3M−0% | 19.3M−0% | 19.2M−1% | 19.1M−2% | 19.1M−1% | 19.1M−1% | 18.5M−3% | 18.3M−4% | 18.3M−4% | 18.4M−4% | 18.5M−0% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY10 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: share-days: the 12-month average over 364 days less the 9-month over 273, the two on one basis (x2). Q4 FY17 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Usana Health Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| USNAUsana Health Sciences | $257.9M | n/m | 15.6× | 0.3× | +2% | −2.4% | |
| NAGENiagen Bioscience | $192.3M | 13.5× | 27.0× | 1.5× | +11% | 12.4% | |
| FTLFFitlife Brands | $78.4M | 13.5× | 15.3× | 0.8× | +61% | 6.2% | |
| FTKFlotek Industries | $865.7M | 24.1× | 27.6× | 3.0× | +37% | 13.0% | |
| CRONCronos | $1.2B | 16.8× | 25.0× | 6.9× | +37% | 39.1% | |
| BTMDbiote | $38.4M | 10.7× | 12.3× | 0.2× | −8% | 3.2% | |
| ROGRogers | $2.2B | 71.4× | 34.3× | 2.7× | +5% | 3.7% | |
| NGVTIngevity | $2.4B | 47.4× | 19.9× | 2.1× | −4% | 4.7% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| Peer median | $1B | 18.4× | 23.6× | 1.8× | +8% | 6.4% |
More on Usana Health Sciences
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 106Materials stocks with the lowest EV/EBIT
- #1of 23Chemicals stocks with the lowest EV/EBIT
- #10of 43Chemicals stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .